Nutritional Advice El Mondo
Objectives:
C-reactive protein (CRP) has been proposed as a risk marker and risk factor of cardiovascular disease. There have been a number of clinical reports suggesting that supplementation with L-carnitine can modulate systemic inflammation and lower circulating CRP concentrations, but the results have not been consistent. Therefore, this review article (meta-analysis) has been conducted.
Does supplementation with L-carnitine reduce circulating CRP concentrations?
Study design:
This review article included 6 RCTs comprising 541 cases and 546 controls.
3 studies were conducted in diabetic or prediabetic patients, 2 studies in hemodialysis patients and 1 study in patients with non-alcoholic steatohepatitis.
Duration of L-carnitine supplementation ranged between 8 to 48 weeks.
Dosage of L-carnitine ranged between 1-2 g/day in all the included trials.
Results and conclusions:
The investigators found in random effect analysis a statistically significant pooled effect size [net change = -0.39 mg/L, 95% CI = -0.62 to -0.16, p = 0.001, I2 = 44%, p = 0.11] for the impact of L-carnitine supplementation among 541 cases and 546 controls. This effect size estimate was found to be robust and remained unaffected by the removal of each single study.
The investigators concluded the present meta-analysis support the clinically relevant benefit of L-carnitine supplementation (1-2 g/day) in lowering the circulating levels of CRP. Conducting future, large-scale, randomized clinical trials is warranted in homogenous populations to verify the findings of this meta-analysis.
Original title:
Effect of L-carnitine Supplementation on Circulating C-reactive Protein Levels: A Systematic Review and Meta-Analysis by Sahebkar A.
Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922328/
Additional information of El Mondo:
Find more information/studies on L-carnitine and chronic diseases right here.
Higher circulating levels of CRP increase inflammation.